Mark Trusheim
Impact in
- Economics and Econometrics top 5%
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Statistics and Probability top 5%
- Statistical Methods in Clinical Trials
Papers in
-
- Health Systems, Economic Evaluations, Quality of Life 22
- Pharmaceutical Economics and Policy 19
- Innovation Policy and R&D 4
-
- Biotechnology and Related Fields 7
- Co-authors
- Ernst R. Berndt (15 shared papers)Frank L. Douglas (1 shared paper)Robert L. Jackson (2 shared papers)Casey Quinn (5 shared papers)Colin M. Young (5 shared papers)Peter B. Bach (2 shared papers)William M. Cassidy (1 shared paper)Jonathan C. Thomas (1 shared paper)
- Journals
- Drug Discovery Today (6 papers)Nature Reviews Drug Discovery (5 papers)Clinical Pharmacology & Therapeutics (5 papers)Therapeutic Innovation & Regulatory Science (2 papers)Pharmacogenomics (1 paper)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
Mark Trusheim
40 papers receiving 992 citations
Peers
Comparison fields: 5 of 142
- Economics and Econometrics 297
- Statistics and Probability 84
- Pharmacology 70
- Immunology 124
- Physiology 103
Countries citing papers authored by Mark Trusheim
This map shows the geographic impact of Mark Trusheim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Trusheim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Trusheim more than expected).
Fields of papers citing papers by Mark Trusheim
This network shows the impact of papers produced by Mark Trusheim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Trusheim. The network helps show where Mark Trusheim may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Trusheim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 379 | |
| 2 | 2011 | 70 | |
| 3 | 2016 | 61 | |
| 4 | 2019 | 57 | |
| 5 | 2018 | 57 | |
| 6 | 2016 | 46 | |
| 7 | 2021 | 37 | |
| 8 | 2020 | 33 | |
| 9 | 1982 | 33 | |
| 10 | 1983 | 31 | |
| 11 | 2021 | 24 | |
| 12 | 2021 | 22 | |
| 13 | 2010 | 17 | |
| 14 | 2016 | 17 | |
| 15 | 2012 | 15 | |
| 16 | 2015 | 14 | |
| 17 | 2021 | 13 | |
| 18 | 2013 | 13 | |
| 19 | 2024 | 12 | |
| 20 | 2015 | 12 |
About Mark Trusheim
Mark Trusheim is a scholar working on Economics and Econometrics, Public Health, Environmental and Occupational Health, Immunology, Physiology and General Health Professions, having authored 44 papers that have together received 1.1k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (22 papers), Pharmaceutical Economics and Policy (19 papers), Biosimilars and Bioanalytical Methods (8 papers), Biotechnology and Related Fields (7 papers), Biomedical Ethics and Regulation (5 papers), Innovation Policy and R&D (4 papers), Computational Drug Discovery Methods (4 papers) and Statistical Methods in Clinical Trials (4 papers). The work is most often cited by research in Economics and Econometrics (297 citations), Statistics and Probability (84 citations), Pharmacology (70 citations), Immunology (124 citations) and Physiology (103 citations). Mark Trusheim has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Ernst R. Berndt, Frank L. Douglas, Robert L. Jackson, Casey Quinn, Colin M. Young, Peter B. Bach, William M. Cassidy, Jonathan C. Thomas, Gigi Hirsch and Murray Aitken. Their work appears in journals such as Drug Discovery Today, Nature Reviews Drug Discovery, Clinical Pharmacology & Therapeutics, Therapeutic Innovation & Regulatory Science and Pharmacogenomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.